Literature DB >> 33012718

Mantle cell lymphoma: a rare cause for a swollen palate.

Ayah Mohamed1, Rachel Cowie2, Dáire Shanahan2.   

Abstract

We describe the case of a 68-year-old woman who was referred to the Oral Medicine Department in the Bristol Dental Hospital in November 2018 regarding a mass in the hard palate. The patient was previously diagnosed with stage IV mantle cell lymphoma of the upper tarsal conjunctiva in December 2014. Further investigations revealed lymphomatous deposits in other sites throughout the body. This patient underwent six cycles of chemotherapy, followed by consolidation LACE autograph and maintenance rituximab. While mantle cell lymphoma very rarely presents on the hard palate, knowledge of its clinical features and differential diagnoses is imperative in its accurate diagnosis and appropriate management. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  dentistry and oral medicine; pathology

Mesh:

Year:  2020        PMID: 33012718      PMCID: PMC7536779          DOI: 10.1136/bcr-2020-238332

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  9 in total

1.  Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.

Authors:  Steven Le Gouill; Catherine Thieblemont; Lucie Oberic; Anne Moreau; Krimo Bouabdallah; Caroline Dartigeas; Gandhi Damaj; Thomas Gastinne; Vincent Ribrag; Pierre Feugier; Olivier Casasnovas; Hacène Zerazhi; Corinne Haioun; Hervé Maisonneuve; Roch Houot; Fabrice Jardin; Eric Van Den Neste; Olivier Tournilhac; Katell Le Dû; Franck Morschhauser; Guillaume Cartron; Luc-Matthieu Fornecker; Danielle Canioni; Mary Callanan; Marie C Béné; Gilles Salles; Hervé Tilly; Thierry Lamy; Remy Gressin; Olivier Hermine
Journal:  N Engl J Med       Date:  2017-09-28       Impact factor: 91.245

2.  Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.

Authors:  Mathias J Rummel; Norbert Niederle; Georg Maschmeyer; G Andre Banat; Ulrich von Grünhagen; Christoph Losem; Dorothea Kofahl-Krause; Gerhard Heil; Manfred Welslau; Christina Balser; Ulrich Kaiser; Eckhart Weidmann; Heinz Dürk; Harald Ballo; Martina Stauch; Fritz Roller; Juergen Barth; Dieter Hoelzer; Axel Hinke; Wolfram Brugger
Journal:  Lancet       Date:  2013-02-20       Impact factor: 79.321

Review 3.  Lymphoid lesions of the head and neck: a model of lymphocyte homing and lymphomagenesis.

Authors:  Elaine S Jaffe
Journal:  Mod Pathol       Date:  2002-03       Impact factor: 7.842

4.  Mantle cell lymphoma of the hard palate: a case report and review of the differential diagnosis based on the histomorphology and immunophenotyping pattern.

Authors:  Chung-Che Chang; J Jordi Rowe; Philip Hawkins; Ezedin M Sadeghi
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2003-09

Review 5.  Mantle cell lymphoma of the oral cavity: case series and comprehensive review of the literature.

Authors:  Kelly Guggisberg; Richard C K Jordan
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2009-10-31

Review 6.  Therapeutic options in mantle cell lymphoma.

Authors:  Saar Gill; David Ritchie
Journal:  Leuk Lymphoma       Date:  2008-03

7.  Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.

Authors:  Olivier Hermine; Eva Hoster; Jan Walewski; André Bosly; Stephan Stilgenbauer; Catherine Thieblemont; Michal Szymczyk; Reda Bouabdallah; Michael Kneba; Michael Hallek; Gilles Salles; Pierre Feugier; Vincent Ribrag; Josef Birkmann; Roswitha Forstpointner; Corinne Haioun; Mathias Hänel; René Olivier Casasnovas; Jürgen Finke; Norma Peter; Kamal Bouabdallah; Catherine Sebban; Thomas Fischer; Ulrich Dührsen; Bernd Metzner; Georg Maschmeyer; Lothar Kanz; Christian Schmidt; Richard Delarue; Nicole Brousse; Wolfram Klapper; Elizabeth Macintyre; Marie-Hélène Delfau-Larue; Christiane Pott; Wolfgang Hiddemann; Michael Unterhalt; Martin Dreyling
Journal:  Lancet       Date:  2016-06-14       Impact factor: 79.321

8.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Authors:  Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

Review 9.  Current overview and treatment of mantle cell lymphoma.

Authors:  Michael Schieber; Leo I Gordon; Reem Karmali
Journal:  F1000Res       Date:  2018-07-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.